EnteroSatys Metabolism is based on Hafnia alvei combined in a patented formulation with zinc and chromium, for the EU claim contributes to the normal metabolism of macronutrients (glucids and lipids). It is a premium, highly stable (36 months at room temperature) probiotic available for distribution in many countries.
Constipation • Intestinal transit • Anti-inflammatory • Reduction of gastro-intestinal discomfort • Inhibition of pathogenic E. coli • Restoration of a better dietary ω-6/ω-3 balance • Conjugated linoleic acids (CLA) production • Prospective use in the treatment of obesity • Cystitis • Inhibition of E. coli • Oxalate degradation • Reduction of intestinal inflammation • Potential reduction …
Restoration of a better dietary ω-6/ω-3 balance • Conjugated linoleic acids (CLA) production • Prospective use in the treatment of obesity • Cholesterol management
Weight management • Vaginal health • Rebalance of a healthy vaginal microbiota
L. rhamnosus HA-114 is an innovative patent-pending probiotic strain able to improve eating and mood-related behaviors in overweight adults undergoing a diet-induced weight loss. It could favor wellness and facilitate adherence during a diet-based weight reduction program, through its action on the brain-gut axis. L. rhamnosus HA-114 supports weight management efforts during a diet (eating …
Hafnia alvei is the first precision probiotic developed based on a target-based approach and a screening for strains producing ClpB, a protein mimicking alpha-MSH and activating the signals of satiety. Its mechanism of action and demonstration in efficacy in mice and humans make it a uniquely positioned, innovative next-gen probiotic for weight management.